E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of moderate to severe acute pain after elective unilateral total hip arthoplasty |
|
E.1.1.1 | Medical condition in easily understood language |
Treatment of acute pain after surgical replacement of hip joint |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066714 |
E.1.2 | Term | Acute pain |
E.1.2 | System Organ Class | 100000004867 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the analgesic efficacy of oral DKP.TRIS and TRAM.HCl fixed combination on moderate to severe pain after elective hip arthroplasty. |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and tolerability of the treatment after single and 5-day repeated doses. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Male or female patients aged 18 to 80 years. Females participating in the study must be either: of non-childbearing potential, or willing to use a highly contraceptive method.
2.Scheduled to undergo standard primary (first-time) one-sided total hip replacement surgery due to osteoarthritis (excluding osteoarthritis secondary to systemic/metabolic diseases, trauma or infections) and requiring hospitalization for at least 5 days after the surgery.
3.ASA (American Society of Anaesthesiologists) Patient Classification Status I, II or III.
4.Patients experiencing pain at rest of at least moderate intensity (PI-VAS ≥ 40 mm) the day after surgery who are capable of swallowing oral medication and suitable to be randomized and dosed by 10:00 a.m.
|
|
E.4 | Principal exclusion criteria |
1.Patients who are judged by the Investigator not to be suitable candidates for study treatments and RM based on their medical history, physical examination, concomitant medication (CM) and concurrent systemic diseases.
2.Patients with clinically significant abnormalities of vital signs (VS), safety laboratory tests and 12-lead ECG at screening.
3.Patients with history of allergy or hypersensitivity to the study drugs, RM or to any other NSAIDs, opioids, acetyl salicylic acid, pyrazolones or pyrazolidines.
4.Patients with history of peptic ulcer, gastrointestinal disorders by NSAIDs or gastrointestinal bleeding or other active bleedings.
5.Patients with history of severe asthma.
6.Patients with moderate to severe renal dysfunction, severe hepatic dysfunction or severe cardiac dysfunction.
7.Patients with coagulation disorders.
8.Patients with history or current epilepsy.
9.Patients with Crohn’s disease or ulcerative colitis.
10.Patients with acute intermittent hepatic porphyria.
11.Patients with congenital G6PD (glucose-6-phosphate dehydro-genase) deficiency.
12.Patients with impaired bone marrow function (e.g. following treatment with cytostatic drugs) or haematopoiesis disorders.
13.Patients using and not suitable for withdrawing analgesics, other than those specified in the protocol, from the end of surgery (5 days before surgery in case of COX-2 inhibitors) up to completion of last study assessment (i.e. 8 hours after last intake of study medication).
14.Patients under chronic opioid treatment (major opioids and tramadol).
15.Patients using and not suitable for withdrawing the prohibited medication, within 48 hours or 5 half-lives (whichever is the longer) prior to the start of surgery and up to 24 hours after the last intake of study medication:
-Anticoagulants, thrombolytic and antiplatelet agents (except standard peri-operative use for thrombo-embolic prophylaxis and ≤ 325 mg aspirin for cardiovascular prophylaxis);
-Corticosteroids (with the exception of inhalers or topical agents);
-Monoamine oxidase (MAO) inhibitors (a minimum of 14 days must
elapse prior to the start of surgery);
-Antiepileptics;
-Antipsychotics;
-Serotonin reuptake inhibitors and tricyclic antidepressants;
-Lithium;
- Methotrexate;
- Antibacterial sulfonamides.
16.Patients receiving concomitant treatment with other investigational drugs or who have participated in other clinical trial within 4 weeks before entering the study.
17.Patients with history of drug or alcohol abuse. For the purpose of the study, alcohol abuse is defined as regularly intake of more than 4 units of alcohol per day (1 unit corresponds approximately to 125 ml wine, 200 ml beer, 25 ml spirit).
18.Patients with a history of any illness or condition, that in the opinion of the Investigator might pose a risk to the patient or confound the efficacy and safety results of the study.
19.Pregnant and breastfeeding women.
20.Patients experiencing any surgical complication that, in the opinion of the Investigator, advises against their inclusion in the study.
21.Patients who are exposed to ondansetron (or other 5-HT-3 receptor antagonist antiemetics) on the day of randomization. NOTE: 5-HT-3 receptor antagonist antiemetics are prohibited from the day of randomization up to completion of last study assessment (i.e. 8 hours after last intake of study medication).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
-Mean SPID at rest (Sum of Pain Intensity Differences, calculated as the weighted sum of the PID-VAS values), over 8 hours after the first dose (SPID8).
The primary efficacy variable will be used for the assessment of the co-primary efficacy endpoint to test the superiority of DKP.TRIS + TRAM.HCl versus DKP.TRIS and versus TRAM.HCl administered as single agents in the single-dose phase.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
over 8 hours after the first dose |
|
E.5.2 | Secondary end point(s) |
Pain intensity
-Mean PI-VAS scores at rest, over 8 hours after the first dose.
-Percentage of responders (response defined as achievement of a mean PI-VAS < 40 mm at rest) at 2, 4, 6, 8 hours after the first dose.
-Mean SPID at rest, over 2, 4 and 6 hours after the first dose (SPID2, SPID4, SPID6).
-Mean % max SPID at rest, over 2, 4, 6 and 8 hours after the first dose (max SPID calculated as the theoretical maximum weighted sum of the PID-VAS values).
-Mean PI-VAS scores at rest over 48 hours of the multiple-dose phase.
-Percentage of responders (response defined as achievement a mean PI-VAS < 40 mm), over 48 hours of the multiple-dose phase.
-Mean SPID, over 24 and 48 hours of the multiple-dose phase.
-Mean % max SPID, over 24 and 48 hours of the multiple-dose phase.
Pain relief
-Mean PAR-VRS scores, over 8 hours after the first dose.
-Mean TOTPAR, calculated as the weighted sum of the PAR-VRS scores, over 4, 6 and 8 hours after the first dose (TOTPAR4, TOTPAR 6, TOTPAR8).
-Percentage of responders over 8 hours after the first dose, according to the 50 % maximum total pain relief rule (max TOTPAR calculated as the theoretical maximum weighted sum of the PAR-VRS scores).
Rescue medication
-Time to first use of RM: time elapsed between treatment administration and first RM intake.
-Use of RM (i.e. patients who require at least one dose of RM and amount of RM consumption) overall and over 24 and 48 hours of the multiple-dose phase.
Others
-PGE at the end of the single-dose phase (t8h); and during the multiple-dose phase on day 3 and day 5, eight hours after the morning dose, or whenever patient withdraws from the treatment.
-Worst pain while moving experienced in the previous 24 hours, on day 2 and on day 3.
-Discontinuation from the treatment for any cause (e.g. lack of efficacy, AEs, others).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
see timepoints in the text above |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
China |
Czech Republic |
Germany |
Hungary |
India |
Latvia |
Lithuania |
Spain |
Poland |
Serbia |
Taiwan |
Ukraine |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |